Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
These review articles reflect the presentations that were given at a conference held in Dallas, Texas, in January 1999. Both the conference and this series sought to establish the criteria necessary for measuring remission, or wellness, in patients with depression, anxiety, or comorbid depression with anxiety and to evaluate the pharmacotherapeutic options best suited to meet these new standards.
Today, depression and anxiety are viewed as two ends of a continuum, with a significant degree of comorbidity occurring between them1; two thirds of patients with depression have experienced a previous anxiety disorder. The highest rate of anxiety comorbid with depression occurs with generalized anxiety disorder (GAD).
Save
Cite
Advertisement
GAM ID: sidebar-top